Tesla's $25 Billion Capex Plan Is No Longer About Cars. Here's Why Tesla Could Be the Most Undervalued AI and Robotics Stock of 2026.

Tesla raised its 2025 capital spending plan to $25 billion from $20 billion and outlined six major investments, including a Cybercab production facility, Tesla Semi, a new Megafactory, a lithium refinery, and Optimus robot production lines. The article argues these investments position Tesla for future recurring revenue from robotaxi ride-share and Optimus robot-as-a-service, with FSD v15 expected in late 2026 or early 2027. Wall Street estimates robotaxi and Optimus could account for nearly 13% of revenue by 2028.

Analysis

The market is underestimating how capital allocation is shifting Tesla from a cyclical auto assembler into a vertically integrated compute-and-robotics platform. The spend profile implies the company is trying to control the two scarcest inputs for AI hardware scale: power-dense battery supply and inference-capable chips, which should reduce future bottlenecks and improve gross margin resilience if execution holds. That creates a second-order benefit for upstream suppliers tied to lithium refining, specialty semis, and industrial automation, while putting incremental pressure on legacy EV OEMs that are still fighting for price and mix.

The real catalyst is not near-term revenue, but de-risking the 2027 earnings story. If Tesla gets FSD to a credible unsupervised milestone and establishes a repeatable manufacturing path for Cybercab and Optimus, the valuation debate shifts from unit sales to software-like recurring revenue with much higher lifetime value per asset. The market will likely start repricing before monetization shows up in reported numbers, but only after evidence of technical validation, regulatory progress, and manufacturing ramp quality.

The main bear case is execution drag: heavy capex before product certainty can compress free cash flow and force investors to tolerate a longer proof period. A failure to deliver FSD v15 on schedule, or any safety/regulatory setback in autonomous driving, would likely reset the timeline by 12-24 months and unwind part of the multiple expansion thesis. There is also a supply-chain risk embedded in the chip and battery buildout: if internalized production is late or inefficient, Tesla could end up with higher fixed costs but no corresponding moat widening.

Consensus is treating this as an EV story with optionality, but the more important point is that Tesla is creating call options on two new businesses whose economics are still opaque and therefore under-modeled. That means the stock can grind higher on narrative alone, but the downside is asymmetric if the market decides the capex is front-loaded and the monetization curve is pushed out. The optimal framing is to own upside through defined-risk structures rather than chase the equity outright into an execution-heavy 12-18 month window.

Key Decisions for Investors

• Maintain a tactical long TSLA bias into FSD v15 validation milestones, but express it via 6-12 month call spreads rather than stock; upside is tied to narrative re-rating, while the capped downside protects against execution slippage.
• Pair long TSLA against a basket of legacy EV OEMs or auto suppliers exposed to commoditized EV pricing over the next 6-18 months; the trade monetizes the widening gap between platform optionality and balance-sheet strain.
• Overweight NVDA selectively on any pullback if Tesla's semiconductor ambitions are seen as reinforcing, not replacing, external AI chip demand; the better setup is suppliers of advanced tooling and inference silicon rather than pure end-demand AI names.
• Watch lithium/refining and battery-material names for a 6-12 month catch-up trade: Tesla's internal buildout raises the probability of tighter procurement standards and premium long-term offtake relationships, but only names with low-cost structure and scale should be owned.
• Avoid shorting TSLA outright into the next 2-3 quarters; the stock can rerate on milestone-driven expectations well before revenue inflects, making bearish carry poor unless paired with a catalyst calendar and tight risk controls.